💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, fast-growing business, fairly priced.
Glenmark Pharma is scored on the pharma / healthcare framework. It keeps a slim 7.8% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 2.53× reported profit. Free cash flow is worth about 3.0% of its market value.
Over the last 3 years revenue compounded at 14%/yr and profit at 53%/yr. Book value has been broadly flat (2.2%/yr). Return on equity is an elite 18.1%. In the latest quarter profit grew 60% versus the prior quarter.
At 54× earnings, the stock sits at the 50th percentile of its own 2.6-year range — the middle of where it has historically traded. Today's price already implies ~22%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 50.42 | — | — |
| P/B | 6.53 | 4.1 | worse |
| EV/EBITDA | 25.16 | 19.33 | worse |
| ROE | 18.07 | — | — |
| ROCE | 19.86 | 14.41 | better |
| ROA | 6.78 | 1.64 | better |
| Quick Ratio | 1.23 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 14% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
1 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a +30% swing — check if it's a one-off or structural.
Operating margin has expanded from 2% to 11% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 13% — a respectable return on shareholder capital. Capital efficiency improving — ROE up 14pp across the window.
EPS outpaced profit growth — possible buybacks are concentrating earnings into fewer shares. 114% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
2 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Cash conversion at 2.5× PAT — earnings are well-backed by cash; strong accrual quality.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Wide quarterly swings (37% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate fading — recent quarters 21% below earlier ones.
Profit jumped 60% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (10% → 12%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 2.6y median.
Promoters at 46.6% — dispersed ownership; institutional flows drive the stock. FIIs have accumulated for 3 straight quarters — sustained foreign institutional conviction. MF stake down 2.3pp — domestic funds are booking profits or rebalancing out.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.